SAMHSA Updated TIP 63: Medications for Opioid Use Disorder

This updated version of Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder reviews the use of the three Food and Drug Administration-approved medications used to treat Opioid Use Disorder (OUD)—methadone, naltrexone, and buprenorphine—and other strategies and services needed to support recovery for people with OUD.

Updates include–
• Additional information about the qualifications of practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives) that explains exceptions under the latest buprenorphine practice guidelines on obtaining a waiver.
• Citations that support induction onto extended-release naltrexone of people with positive urine tests for opioids so long as they pass the naloxone challenge.
• Clarification that naltrexone can result in decreased opioid cravings.
• Where needed, clarification of whether discussion about naltrexone refers to the oral formulation or the extended-release injectable formulation.
• Updated statistics on opioid-related deaths, overdoses, accidents, and hospitalizations.
• Updated online resources.

View Publication



National Association of Drug Diversion Investigators Federal Tax ID: 52-1660752 / DUNS Number: 073539913

Copyright © 2021 - NADDI. All Rights Reserved. Privacy Policy / Trademark Policy / Copyright Policy / Refund Policy

Log in with your credentials


Forgot your details?

Create Account